Multiple sclerosis (MS) is a multifaceted condition, with a range of environmental, behavioural and genetic factors implicated in its aetiology and clinical course. Successes in advancing our appreciation of the roles of Epstein-Barr virus, vitamin D/UV and the HLA-DRB1 locus; and our greater understanding of these and related factors' modes of action in MS and other conditions, can be attributed in no small part to the work of generations of epidemiologists. Hardly content to rest on our laurels, however, there are yet a range of unsolved conundrums in MS, including some changes in epidemiological characteristics (e.g. increasing incidence and sex ratio), to say nothing of the unresolved parts regarding what underlies MS risk and its clinical course. There is evidence that epidemiology will continue to play a crucial role in unravelling the architecture of MS causation and clinical course. While classic epidemiological methods are ongoing, novel avenues for research include gene-environment interaction studies, the world of '-omic' research, and the utilisation of mobile and social media tools to both access and track study populations, which means that the epidemiological discoveries of the past century may be but a glimpse of our understanding in the next few decades.
Introduction
Multiple sclerosis (MS) is a complex condition, where the precise aetiological determinants of its onset and clinical course continue to elude medical researchers. However, in pursuit of a greater understanding of what determines the risk of disease and/or a more severe clinical course, epidemiology has been invaluable in efficiently elucidating some of the key behavioural, environmental and genetic factors which modulate risk, including the role of Epstein-Barr virus (EBV), ambient ultraviolet radiation (UVR) and vitamin D levels, tobacco smoking, and the HLA-DR1 locus within the major histocompatibility complex (MHC). These successes, which have led to the ability of neurologists to provide some guidance to patients regarding lifestyle modification to potentially alter their clinical course, and advice to reduce risk in relatives, may yet lead to novel therapeutic interventions. They have only uncovered a portion of the complex tapestry that is MS aetiology. In this paper, we will discuss how epidemiology has contributed in the past to MS research, some of the challenging conundrums that we are still faced with, and some of the emerging developments that will serve to open new avenues for epidemiological research in MS.
The contribution of epidemiological research to MS
The ultimate aim of MS research would be to fully prevent or cure MS. In order to achieve this goal, different types of research need to complement each other, including epidemiological and experimental research, the latter comprising animal experiments, cell studies, and biochemical, genetic and physiological investigations, as well as studies on the properties of drugs and materials. However, given the almost infinite array of targets for experimental study, some refining of the targets of investigation is needed. Here sits the great utility of epidemiology.
Epidemiology is the science that studies the patterns, causes, and effects of health and disease conditions in defined populations. It is this science that has made a substantial contribution to MS research, by its findings of significant variability in various environmental exposures, personal behaviours and genetic variants. These finding have then given impetus and plausibility to investigations of the biological mechanisms underpinning those associations. Epidemiologists observed the geographical differences in MS, the large sex differences, and identified a number of risk factors for MS onset and clinical course; including high biomarkers of Epstein-Barr virus 1 and the related finding of greater frequencies of infectious mononucleosis in MS cases, compared to controls 2 ; a greater frequency of tobacco smoking among cases than controls 3 ; and the much lower sun exposure and vitamin D-related parameters among cases, compared to controls. 4 It is this latter MS aetiological factor (sun exposure and vitamin D making) that illustrates how the discovery of a risk factor of MS may evolve over time, with the use of different types of research. Back in 1921, Davenport 5 noted how MS differed by region. Work by Kurtzke 6 was instrumental in the 1950s through to the 1980s in documenting that there was a latitudinal gradient of MS prevalence; however, it remained unclear what underlay the apparent gradient: whether it was a function of differential migration, 7 environmental differences, 8 or merely confounding 9 or other bias from poor analytical methods. 10 In 1960, it was observed that there was a strong association between ambient UVR and MS prevalence, which persisted after adjustment for latitude 11 ; however, the link between UVR and MS was not intensively investigated, partly because research evidence to support UVR-mediated changes in immune function was not then available. It took until the late 1990s to rekindle the hypothesis, with new insights from a new research area termed photoimmunology, providing a biologically plausible explanation to support the possibility that UVR may have immunosuppressive effects on Th1 cell activity. This resulted in the conduct of a number of observational studies.
The first prevalent case-control study, reported in 2000, had mortality as its outcome and used ambient UVR as a proxy measure of personal UVR 12 ; while the next case-control studies had prevalent cases versus controls as an outcome and personally measured UVR. 13 Later still, the more expensive incident case-control and cohort studies were conducted. [14] [15] [16] Importantly, all consistently found that higher levels of sun exposure, vitamin D levels or vitamin D intake were associated with a lower risk of MS. In the meantime, further biological plausibility was provided by animal studies, which confirmed that UVR was protective in experimental autoimmune encephalomyelitis (EAE), the animal model of central nervous system (CNS) inflammation used to study MS. 17 More recently, genetic studies have identified variability in vitamin D-related genes in MS, including the vitamin D-activating enzyme locus, CYP27B1 18 , vitamin D receptor, VDR 19 , the vitamin breakdown enzyme, CYP24A1, and the identification of a link between the MHC class II allele HLA-DRB1*1501 and vitamin D. 20 While much progress has been made in terms of risk factors of MS, less progress was made in relation to factors that influence the progression of MS. Again, vitamin D seems to be promising, with cohort studies substantiating findings regarding aetiology, and cohort studies building on previous case-control designs to show there are significant associations between vitamin D and both MS onset and clinical course, including relapse and magnetic resonance imaging (MRI) parameters. [21] [22] [23] [24] In line with the observational studies, randomised controlled trials (RCTs) of vitamin D supplementation, either alone or in addition to existing immunomodulatory therapies, are now been undertaken to substantiate these results. While many of these trials are yet ongoing, the few that have been completed have shown some evidence of efficacy. [25] [26] [27] [28] These trials, while mostly of sufficient dosages and duration to assess treatment efficacy, are quite small in sample size. Thus, we are anxiously awaiting the results of the larger trials, including SOLAR, 29 EVIDIMS 30 and PREVANZ. 31 The story of vitamin D/UVR and MS provides a nice example of how research evolves from the observations of patterns in data, leading to hypotheses as to mechanisms, and ultimately, leading to a consensus that factors are truly causally related to a disease or disease progression. The process of causal inference takes time. Using the framework of the Bradford-Hill criteria, at a minimum the process requires consistency in findings, biological plausibility and convincing evidence that the exposure precedes the outcome. Taking all the evidence together, we now have sufficient evidence to nominate sun exposure and vitamin D as causal factors of MS, while we still wait for larger trials to determine their effects on the disease course of MS.
Challenging issues in MS epidemiological research
While substantial progress has been made, there are still many questions to which we do not have complete answers. For example, there have been changes over time that are challenging to explain, including an increase in MS incidence, 32 an increase in the femaleto-male sex ratio in relapsing-remitting MS 33 (RRMS) and an apparent decrease in the latitudinal gradient of MS incidence. 34 We can speculate about what might be causing these changes, but it is challenging to unravel all the factors responsible and to what extent each of them is involved. For example, the increase in incidence seems to be partly due to changes in diagnostic criteria (mostly resulting in an earlier diagnosis) and better case ascertainment by neurologists, but this cannot explain all of the increases seen in some locations, leaving one to consider that part of the effect may be due to lifestyle changes. Low sun exposure may be partly responsible for this, as there is evidence that younger cohorts spend less time outside at the same ages as their older counterparts. 35 Also, socio-political changes in nations like Iran may have contributed to the changing incidence, particularly the increasing female-to-male sex ratio in that nation. 36 In western countries, smoking might not be an important contributor, as the smoking rates in many countries have slowly decreased, rather than increased, over the decades. Interestingly, the prevalence of the potent infectious aetiological factor, EBV, has decreased, rather than increased, 37,38 adding a degree of complication to interpreting the increasing incidence. The increase in female-to-male sex ratio has been proposed to be partly the result of a decline of smoking among men. 39 The change in sex ratio varies substantially in magnitude across the world's regions, probably due to differences over time in sexspecific behaviours.
The ideal study design to assess the factors that would be responsible for these changes over time would be a long-term cohort study (at least 10-20 years) with incidence as an outcome and where data is available on all the potential explanatory variables. The effect of time on incidence can then be modelled; and it can be examined whether changes in putative explanatory variables explain that change. Given the low incidence of MS, these studies are challenging to conduct, leaving us often with indirect methods to examine these changes and less definite proof. In relation to the association between month of birth and MS, such a longitudinal study was reconstructed by Staples et al. 40 The incidence of MS for each month of birth was compared with the incidence in the general population. At the individual level, they allocated the ambient UVR of the region at birth as a proxy for personal UVR exposure. Similar to other studies, they observed a relative excess of MS in people born in November through December (and early summer in the southern hemisphere) compared with the May through June reference minimum (or early winter in the southern hemisphere) and they found that the effect was abrogated after adjustment for the month and regionspecific ambient UVR during the first trimester prior to birth, suggesting that UVR exposure explained the month of birth effect. 40 This finding is in line with the hypothesis that vitamin D plays a critical role in nervous system development, 41 potentially modulating subsequent risk for neurological conditions like MS 42 and schizophrenia. 43 Their finding is further substantiated by a study that showed that the month of birth effect was only present among those with the risk allele, HLA-DRB1*15 44 , which is shown to interact with vitamin D due to the vitamin D-response element in its promoter. 20 Recent work suggests that deviations in the month of birth between samples and the general population are due to confounding and that these deviations are merely due to chance. 45 While this may be a potential explanation, the study by Staples et al. 40 that found the month-of-birth effect to be abrogated on adjustment for maternal sun exposure during pregnancy, and the Ramagopalan et al. 44 study that found the association only present among those with the particular HLA-DRB1 genotype, do give some credence to a true effect. Certainly further work in this area is warranted.
The mechanisms underlying the well-described feature that MS is more common in females than in males still remain much of a mystery. It has long been noted that women with MS have fewer relapses during pregnancy. 46 Recently, our group showed that women with a higher number of offspring had a lower risk of a first clinical diagnosis of a demyelinating event. 47 Importantly, no association was observed in men, suggesting that the apparent protective effect of parity is more likely to relate to prenatal factors to do with the pregnancy, rather than postnatal factors pertaining to the offspring. If the association with parity is shown to be causal, it could partly explain the increase in incidence, particularly among women, as their number of offspring in western populations has decreased over the recent decades. 48 Many suggest sex hormones as underlying the differences by sex in MS 49, 50 ; however, in-depth investigation of the role of sex hormones is challenging in epidemiological study designs, as they vary throughout the menstrual cycle, and so their relationship to onset is therefore hard to interpret.
While immunotherapy treatments have been developed for RRMS, there are no treatments for primary progressive MS (PPMS). Much less is understood about PPMS or secondary progressive MS (SPMS), compared to RRMS. Some dedicated studies describe the natural history of this disease type, [51] [52] [53] but aetiological and clinical course studies are frustrated by infrequency, as only 10% of the cases have a PPMS phenotype, 54 and potential reverse causality issues (changes in behaviour/environment due to disease can incorrectly suggest a role for that behavioural/environmental factor in disease aetiology). For these reasons, many studies have focused on genetic, 55 rather than behavioural and environmental factors, despite the latter being a more readily accessible point of intervention. Accordingly, calls are now out for targeted research for progressive MS. Given the difficulties in research on PPMS, epidemiological studies will require concerted multicentre studies of this population, in order to have sufficient statistical power and representativeness to extrapolate findings to the general PPMS population.
The future of epidemiology in MS research
While there are still many questions and challenges, there are also new opportunities for epidemiological research in MS, some of which we will discuss.
Interplay of genetics and epidemiological research
The large multicentre genome-wide association collaborations have now been able to associate >100 loci with MS onset, many of them related to immune function genes. It is hoped that the knowledge of these genes will unravel mechanisms that can be modulated, and these, in turn, will lead to new treatments. The huge sample sizes that were able to be set up by these collaborations are needed, to deal with the high number of false-positive associations thrown up through the high number of comparisons, leading to p-values of at least 10 −6 being required to have genome-wide significance. Large collaborations are more challenging when examining markers of disease progression, where patients need to be followed over time and where consistency is needed in the measures of disease progression.
Epidemiological studies could assist in a number of ways. Studies that evaluate interactions between genes and environmental factors (gene-environment interactions) can serve to rule in causal associations. Where a priori hypotheses are being evaluated, but some adjustment for multiple comparisons is desired, there may be leave to make use of adjustment for the number of genes being tested, rather than the absolute number of polymorphisms. Furthermore, epidemiological concepts such as consistency between different but related measures like related outcome or exposure measures (e.g. self-reporting and objective assessment of sun exposure or smoking), dose-dependency (e.g. more copies of the potential risk allele from heterozygote to homozygote that show an increase in signal), and of course reproducibility between studies, can contribute to confidence in a true association, despite not having genome-wide significance.
Meta-analyses are another powerful way of combining data. To allow this to happen for geneenvironment interaction studies, we recommend using STROBE/STREGA reporting guidelines, as many studies in the past were inconsistent in their methods of analysing interactions and reporting was also highly variable, as we have described previously. 56 
The potential role of '-omic' technologies in MS research
Beyond classical genetics, there is an expansive world of molecular physiological data in the form of the '-omics'. From genomics (the analysis of the genome), we are now exploring the application of epigenomics, (the analysis of the epigenetic controls on gene expression and protein function); transcriptomics, (the analysis of what components of the genome are actually expressed, and how this changes between cell types and disease states); proteomics, (the analysis of the proteins inside a cell, and how their distribution varies between cell types and disease states); and beyond this, to metabolomics, which can analyse the metabolites in whole-organism waste, or within tissues or other biological samples, to extrapolate a whole group of elements ranging from intake to metabolism at various levels and how this varies by disease type.
All of these fields are in various early stages of development, certainly in comparison with genomic analyses; however, there is a remarkable potential here for hypothesis generation. Despite the two centuries of studying MS epidemiology at varying levels of complexity, we have yet to fully understand the disease. These -omic technologies and their ability to give a snapshot of the activity of cells, tissue and organisms at individual point in time can give signals for what aspects underlying these changes may relate to disease, response to therapy and prognosis. They may show, for example, how the whole of the genetic expression of immune cells changes in response to a stimulus with myelin basic protein; how the proteome of macrophages change between relapse and remission; or how the whole-body or organ-specific metabolomes change in patients, between the before and after of starting treatment with an immunomodulatory agent. These signals, just like previous studies' utilisation of parameters like sun exposure and occurrence of infectious mononucleosis led to our understanding of UV/vitamin D in immune modulation, 57, 58 and EBV and its panoply of potential pathways in MS 58 will give directions to further research, allowing the discovery of novel mechanisms underlying both MS risk and clinical course.
A significant complication is, however, that unlike the genome which is constant throughout an organism (and thus, a peripherally-acquired sample will have the same genome as the cells in the organ/tissue of interest), these other technologies are much more tissue specific. Thus, while to some extent an aberrant profile in a peripherally acquired sample may potentially mirror aberrations in the organ of interest, more likely these technologies will need to evaluate samples from the area of interest. For MS, that means at the very least cerebrospinal fluid (CSF), but given the heterogeneity in cell types within the CNS alone, and the possibility that the aberration of interest will be in a MS-specific cell type such as the oligodendrocyte or microglia, these cell types are more relevant. That such cell types are most likely to be sourced from cadavers is a further concern, as the very nature of these new parameters is highly sensitive to the actual state of the cells being sampled. Thus, the process of death, even the period of decline leading up to death, will perturb the -omic profile that is being assessed. This is not to say that these -omic technologies are wholly impossible to apply in MS research. We can start with the more accessible sites to sample, comparing the -omic profiles in peripherally acquired samples between people with MS and healthy controls, or between MS types, or active/inactive disease. It may be that in the future, advances in the labelling of proteins, or even short sequences of DNA or RNA, may allow the visualisation of the changing -omic profiles in more inaccessible anatomical sites via MRI. Again, there is a remarkable potential for these or other imaging technologies to suggest new areas to investigate, both in epidemiological and molecular biological settings, and to potentially find new risk factors underlying MS onset and clinical course; or better, areas of intervention to exploit, to reduce the risk of disease.
The role of social media and mobile technologies in MS epidemiology
The era of social media and mobile technologies should be taken advantage of, in relation to epidemiological research in MS: It can be used in a range of different ways; for example, for the recruitment of participants, tracking participants, measurement of factors of interest and behavioural/educational delivering interventions.
In relation to tracking participants, particularly in longitudinal cohort studies, the sensitivity of measures is a function of logistical resources on the part of investigators and of the endurance of the participant to fully comply with what is asked for by investigators. It is in both of these aspects that studies are always seeking to enhance the fidelity of their measures, trying to enhance follow-up with the minimal resources required and to get the most data out of their participants without leading to attrition and non-compliance. Previous methods, including paper-based questionnaires at intervals, periodic contacts, or visits with study investigators, nurses and other personnel were the primary modes of assessing exposure and clinical outcome parameters in the past. 59, 60 What we may have in the near future is the ability to monitor parameters of exposure at much closer intervals, with relatively small burden on the participant. It may be possible to make use of social media and mobile technologies, both of which are becoming quite common in most nations, and with some penetrance into older age groups. 66 Given this digital connectedness, there is a great potential to enhance and expedite various aspects of followup. At a minimum, we can fully dispense with paper-based questionnaires, in favour of web-based or other electronic surveys. This reduces the issue of transcription error, allowing for a more comprehensible navigation through questionnaires using conditioning, and of course, reduces the resources needed to produce and transport the questionnaires; however, beyond this, it may be possible to transition away from a staid and pro forma questionnaire, to more customisable and participant-driven reporting. Whereas we had previously asked participants to come in at intervals and complete the same questionnaire as other participants, regardless of their particular situation, we could now potentially have customisable instruments that query parameters of relevance to that participant type. For instance, progressive participants would obviously have no questions regarding relapse, but instead could have a more intensive monitoring of their disability progression over time that is more relevant to them. One could make use of participants' social media (with permission of course), wherein their quality of life may be assessed over time, either indirectly from their posts or even specifically, by having investigator-prompted queries at some interval, which are silently posted only for investigators to see.
One aspect of MS research, which dovetails to some extent with other recurring event outcomes in epidemiology, like infections and falls, is the ability to reliably track the occurrence of these outcomes over time. More often in the past, this had just tracked retrospectively, by querying the occurrence of relapse in some prior interval or reviewing medical records. 61 More recently, studies have sought to make use of realtime monitoring of relapse, by having participants phone investigators when they thought that they were having an episode. 21, 24 Given participants' uncertainty of what is and is not a relapse, and variability in some participants to even report a likely episode, a way of tracking episodes closer to the start of symptoms, but which is not so onerous to participants, is indicated.
Social media such as Twitter, mobile phone-based applications (apps), or even more pedestrian technology such as web-based surveys or email, may provide a mechanism to more reliably track relapses. One could imagine an app that quickly queries relapse symptoms each day, and which automatically alerts investigators to follow up when a participant reports any level of symptoms indicative of relapse. Alternatively, a more participant-driven method like tweeting or emailing investigators about potential relapse symptoms could be utilised, avoiding the need to keep a study nurse on hand at particular hours to receive calls, and being sufficiently quick and simple to do that participants might be more likely to make that contact than if they were immediately having to do a phone assessment with a study nurse.
There are now a number of examples of successfully recruiting participants for epidemiological studies, many showing positive comparability in recruitment by social media and mobile methods, compared to more classical methods, 62, 63 and certainly a greater cost-effectiveness. 62, [64] [65] [66] There is necessarily a limitation in that the populations accessed by these methods will vary as a function of age and access to technology; however, similar issues have arisen with the use of classical methods, like landline phone communication, particularly among younger populations. 67, 68 The reverse age limitation is found with social media and mobile methods 66 . It may be that for a period, these methods may complement one another to yield a more representative sample, where the population assessed has a broad range of demographic characteristics.
Conclusions
Epidemiology has contributed greatly to our understanding of MS, both in terms of its onset, its clinical course and how risk factors relate to one another. While there are still conundrums in MS epidemiology that remain to be teased out, there is also an expansive future from exploration of various cellular and organismal -omic profiles, which will revolutionise our understanding of MS. Moreover, the logistical implications of online/app-based follow-up to allow tracking of participants with greater fidelity but at reduced cost may yet revolutionise the fashion in which observational studies and clinical trials are undertaken. Epidemiology has played a significant role in MS research up to now, and will remain to play a key role, albeit in different ways compared to the past. We await with bated breath the epidemiological discoveries of tomorrow. 
